Format

Send to

Choose Destination
Breast Cancer Res Treat. 2020 Feb;180(1):187-195. doi: 10.1007/s10549-019-05518-z. Epub 2020 Jan 7.

Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.

Author information

1
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. song.yao@roswellpark.org.
2
Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
3
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
4
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Abstract

PURPOSE:

Osteoporosis and fragility fracture are major bone toxicities of aromatase inhibitors (AIs) for postmenopausal hormone receptor-positive breast cancer. Except for a few small studies on bone turnover markers and reduced bone mineral density after AI treatment, data on the associations of bone markers and risk of osteoporosis or fracture from prospective studies are lacking.

METHODS:

In a prospective study of 1709 women on AIs, two bone turnover markers, BALP and TRACP, and two bone regulatory markers, RANKL and OPG, were measured and examined in relation to risk of osteoporosis and fragility fractures during a median follow-up time of 6.1 years.

RESULTS:

Higher levels of BALP and TRACP were both associated with increased risk of osteoporosis and higher BALP/TRACP ratios were associated with lower risk of osteoporosis, but no associations were observed for fracture risk. Higher levels of OPG were associated with increased risk of fracture, whereas higher levels of RANKL were associated with lower risk. As a result, OPG/RANKL ratios were positively associated with fracture risk [hazard ratio (HR) = 2.49, 95% confidence interval (CI) 1.34-4.61]. After controlling for age and fracture history, the associations became non-significant but a suggestive trend remained (HR = 1.80, 95% CI 0.96-3.37).

CONCLUSION:

Our study provides suggestive evidence for the potential utility of OPG/RANKL ratios in predicting risk of fracture in women treated with AIs for breast cancer. Further validation may be warranted.

KEYWORDS:

Bone markers; Breast cancer; Fracture; Osteoporosis

PMID:
31912328
DOI:
10.1007/s10549-019-05518-z

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center